Literature DB >> 8858527

Pathology of meningiomas.

L A Langford1.   

Abstract

Because meningiomas arise from arachnoid cells present in the meninges, they can occur in any location where meninges or ectopic meninges exist, such as the nasal cavity, the paranasal sinuses, the middle ear, and even the mediastinum. Although the tumors may range in appearance from epithelial to mesenchymal, they are characterized by a uniform distribution of cells with shapes ranging from polygonal epithelial-like to spindled and fusiform. Historically, classification of meningiomas has been based upon cell shapes, cell patterns, cell products, or stroma, implying clinicopathologic differences among the types. Numerous observations have shown that certain conditions may indicate a predisposition for developing meningiomas, prompting extensive studies of meningiomas using cytogenetic techniques. Meningiomas are common neoplasms arising from the central nervous system meninges. They are important because of the morbidity they produce. Their critical intracranial and intraspinal locations make diagnosis and surgical removal difficult.

Entities:  

Mesh:

Year:  1996        PMID: 8858527     DOI: 10.1007/bf00165651

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  17 in total

Review 1.  The molecular genetics of meningiomas.

Authors:  V P Collins; M Nordenskjöld; J P Dumanski
Journal:  Brain Pathol       Date:  1990-09       Impact factor: 6.508

2.  Histological subtypes and prognostic problems in meningiomas.

Authors:  K Jellinger; F Slowik
Journal:  J Neurol       Date:  1975       Impact factor: 4.849

3.  Germline deletion in a neurofibromatosis type 2 kindred inactivates the NF2 gene and a candidate meningioma locus.

Authors:  M Sanson; C Marineau; C Desmaze; M Lutchman; M Ruttledge; C Baron; S Narod; O Delattre; G Lenoir; G Thomas
Journal:  Hum Mol Genet       Date:  1993-08       Impact factor: 6.150

4.  Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance.

Authors:  H Maier; D Ofner; A Hittmair; K Kitz; H Budka
Journal:  J Neurosurg       Date:  1992-10       Impact factor: 5.115

5.  Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas.

Authors:  M H Ruttledge; J Sarrazin; S Rangaratnam; C M Phelan; E Twist; P Merel; O Delattre; G Thomas; M Nordenskjöld; V P Collins
Journal:  Nat Genet       Date:  1994-02       Impact factor: 38.330

Review 6.  Epidemiology of intracranial meningioma.

Authors:  W T Longstreth; L K Dennis; V M McGuire; M T Drangsholt; T D Koepsell
Journal:  Cancer       Date:  1993-08-01       Impact factor: 6.860

7.  Familial meningioma is not allelic to neurofibromatosis 2.

Authors:  S M Pulst; G A Rouleau; C Marineau; P Fain; J P Sieb
Journal:  Neurology       Date:  1993-10       Impact factor: 9.910

8.  Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2.

Authors:  G A Rouleau; P Merel; M Lutchman; M Sanson; J Zucman; C Marineau; K Hoang-Xuan; S Demczuk; C Desmaze; B Plougastel
Journal:  Nature       Date:  1993-06-10       Impact factor: 49.962

9.  Analysis of chromosome 22 deletions in neurofibromatosis type 2-related tumors.

Authors:  R K Wolff; K A Frazer; R K Jackler; M J Lanser; L H Pitts; D R Cox
Journal:  Am J Hum Genet       Date:  1992-09       Impact factor: 11.025

10.  Deletion mapping of a locus on human chromosome 22 involved in the oncogenesis of meningioma.

Authors:  J P Dumanski; E Carlbom; V P Collins; M Nordenskjöld
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

View more
  2 in total

1.  Primary extracranial meningioma presenting as a cheek mass.

Authors:  Jin Woo Maeng; Yong Hyun Kim; Jinwon Seo; Si Whan Kim
Journal:  Clin Exp Otorhinolaryngol       Date:  2013-11-29       Impact factor: 3.372

2.  Meningiomas in Singapore: demographic and biological characteristics.

Authors:  A Das; W Y Tang; D R Smith
Journal:  J Neurooncol       Date:  2000-04       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.